Kang LI,Jing SONG,Tong ZHANG,Yucheng LI,Zhiying REN,Yanshen KANG
申请号：
US16704738
公开号：
US20200283527A1
申请日:
2019.12.05
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.
